Open Adoptions: Longitudinal Outcomes for the Adoption Triad

Author(s):  
Ruth Mcroy ◽  
Harold Grotevant ◽  
Susan Ayers-Lopez ◽  
Susan Henney
Author(s):  
Seong Hee Kang ◽  
Minjong Lee ◽  
Moon Young Kim ◽  
Jun Hyeok Lee ◽  
Baek Gyu Jun ◽  
...  

Author(s):  
Nancy M. Rodig ◽  
Jennifer Roem ◽  
Michael F. Schneider ◽  
Patricia W. Seo-Mayer ◽  
Kimberly J. Reidy ◽  
...  

2012 ◽  
Vol 39 (11) ◽  
pp. 2413-2430 ◽  
Author(s):  
Samuel Iddi ◽  
Geert Molenberghs

ASAIO Journal ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nicholas F. Smith ◽  
Sina Salehi Omran ◽  
Michael V. Genuardi ◽  
Edward T. Horn ◽  
Arman Kilic ◽  
...  

2018 ◽  
Vol 49 (5) ◽  
pp. 727-737 ◽  
Author(s):  
Michael H. Connors ◽  
Lena Quinto ◽  
Henry Brodaty

AbstractDepression and a number of other psychiatric conditions can impair cognition and give the appearance of neurodegenerative disease. Collectively, this group of disorders is known as ‘pseudodementia’ and are important to identify given their potential reversibility with treatment. Despite considerable interest historically, the longitudinal outcomes of patients with pseudodementia remain unclear. We conducted a systematic review of longitudinal studies of pseudodementia. Bibliographic databases were searched using a wide range of search terms. Two reviewers independently assessed papers for inclusion, rated study quality, and extracted data. The search identified 18 studies with follow-up varying from several weeks to 18 years. Overall, 284 patients were studied, including 238 patients with depression, 18 with conversion disorder, 14 with psychosis, and 11 with bipolar disorder. Irrespective of diagnosis, 33% developed irreversible dementia at follow-up, 53% no longer met criteria for dementia, and 15% were lost to follow-up. Considerable variability was identified, with younger age at baseline, but not follow-up duration, associated with better outcomes. ECT and pharmacological interventions were also reported to be beneficial, though findings were limited by the poor quality of the studies. Overall, the findings suggest that pseudodementia may confer an increased risk of irreversible dementia in older patients. The findings also indicate, however, that a significant proportion improve, while many remain burdened with their psychiatric condition, independent of organic dementia. The findings support the clinical value of the construct and the need for its re-examination in light of developments in neuroimaging, genomics, other investigative tools, and trial methodology.


2018 ◽  
Vol 28 (10-11) ◽  
pp. 3392-3403 ◽  
Author(s):  
Jue Wang ◽  
Sheng Luo

Impairment caused by Amyotrophic lateral sclerosis (ALS) is multidimensional (e.g. bulbar, fine motor, gross motor) and progressive. Its multidimensional nature precludes a single outcome to measure disease progression. Clinical trials of ALS use multiple longitudinal outcomes to assess the treatment effects on overall improvement. A terminal event such as death or dropout can stop the follow-up process. Moreover, the time to the terminal event may be dependent on the multivariate longitudinal measurements. In this article, we develop a joint model consisting of a multidimensional latent trait linear mixed model (MLTLMM) for the multiple longitudinal outcomes, and a proportional hazards model with piecewise constant baseline hazard for the event time data. Shared random effects are used to link together two models. The model inference is conducted using a Bayesian framework via Markov chain Monte Carlo simulation implemented in Stan language. Our proposed model is evaluated by simulation studies and is applied to the Ceftriaxone study, a motivating clinical trial assessing the effect of ceftriaxone on ALS patients.


Sign in / Sign up

Export Citation Format

Share Document